Crucell N.V. Announces Completion Of Acquisition Of SBL Vaccin AB

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- November 23, 2006 -- Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (NASDAQ: CRXL) (Swiss Exchange: CRX) announced today that it has completed the acquisition of SBL Vaccin AB.

MORE ON THIS TOPIC